Diabetes patients on nasal GLP-1 show better outcomes

05/2/2014 | Healio (free registration)

A small Japanese study published in Diabetes Care revealed intranasal GLP-1 helped recover insulin secretion and inhibit glucagon production in type 2 diabetes patients. Researchers also observed lower glycoalbumin levels and increased 1,5-anhydroglucitol levels in the nasal GLP-1 group, with no marked adverse events. However, the findings warrant further assessment, researchers said.

View Full Article in:

Healio (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA